Most cited papers from Aurum Institute

Aurum Institute

What are the most cited papers from Aurum Institute?

The most cited paper from Aurum Institute is "Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women" (Jeanne Marisa Marrazzo et al., 2015), with 1,316 citations. Next come "The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis" (846) and "The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis" (706).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 131 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women Jeanne Marisa Marrazzo et al. · New England Journal of Medicine Open access	4 Feb 2015	1,316
2	The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis Andreas Henri Diacon et al. · New England Journal of Medicine Open access	3 Jun 2009	846
3	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis Keertan Dheda et al. · The Lancet Respiratory Medicine	23 Mar 2017	706
4	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Vivek Shinde et al. · New England Journal of Medicine Open access	5 May 2021	667
5	Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis Dereck R. Tait et al. · New England Journal of Medicine Open access	29 Oct 2019	623
6	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response Salim S. Abdool Karim, Gavin Churchyard, Quarraisha Abdool Karim et al. · The Lancet Open access	26 Aug 2009	550
7	Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies Leigh Francis Johnson, Joël Mossong, Rob Dorrington et al. · PLoS Medicine Open access	9 Apr 2013	450
8	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis Amina Jindani et al. · New England Journal of Medicine Open access	22 Oct 2014	446
9	Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment Elizabeth Lucy Corbett, Barbara J. Marston, Gavin Churchyard et al. · The Lancet	Mar 2006	446
10	Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis Olivier Van Der Meeren et al. · New England Journal of Medicine Open access	25 Sep 2018	425
11	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies Haileyesus Getahun, Wanitchaya Kittikraisak, Charles M. Heilig et al. · PLoS Medicine ReviewOpen access	18 Jan 2011	418
12	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects Alimuddin I. Zumla, Martin Rao, Robert S. Wallis et al. · The Lancet Infectious Diseases Open access	21 Mar 2016	404
13	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial Martin Johan Boeree et al. · The Lancet Infectious Diseases Open access	26 Oct 2016	393
14	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Glenda Gray et al. · The Lancet Infectious Diseases Open access	20 May 2011	393
15	A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis Marjorie Z. Imperial, Payam Nahid, Patrick P. J. Phillips et al. · Nature Medicine Open access	26 Oct 2018	391
16	Building a tuberculosis-free world: The Lancet Commission on tuberculosis Michael J. A. Reid et al. · The Lancet Open access	Mar 2019	379
17	What We Know About Tuberculosis Transmission: An Overview Gavin Churchyard, Peter S. Kim, Neha Shah et al. · The Journal of Infectious Diseases Open access	25 Jul 2017	347
18	Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection Jason D. Simmons, Catherine M. Stein, Chetan Seshadri et al. · Nature reviews. Immunology ReviewOpen access	12 Jun 2018	331
19	Achieving the health Millennium Development Goals for South Africa: challenges and priorities Mickey Chopra, Joy Elizabeth Lawn, David M. Sanders et al. · The Lancet	26 Aug 2009	319
20	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions Keertan Dheda et al. · The Lancet Respiratory Medicine Open access	23 Mar 2022	312
21	Advancing host-directed therapy for tuberculosis Robert S. Wallis, Richard Hafner · Nature reviews. Immunology Review	13 Mar 2015	296
22	Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons Colleen Frances Kelley et al. · New England Journal of Medicine	27 Nov 2024	285
23	Post-tuberculosis lung health: perspectives from the First International Symposium Brian Allwood et al. · The International Journal of Tuberculosis and Lung Disease Open access	Aug 2020	279
24	Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort Elise Landais et al. · PLoS Pathogens Open access	14 Jan 2016	278
25	Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers Robert S. Wallis, Markus J. Maeurer, Peter Mwaba et al. · The Lancet Infectious Diseases Open access	22 Mar 2016	264
26	Host-directed immunotherapy of viral and bacterial infections: past, present and future Robert S. Wallis, Anne O’Garra, Alan Sher et al. · Nature reviews. Immunology ReviewOpen access	7 Jun 2022	262
27	The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges Pren Naidoo, Grant Theron, Molebogeng Xheedha Rangaka et al. · The Journal of Infectious Diseases Open access	20 Jul 2017	256
28	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study Morna Cornell, Michael Schomaker, Daniela Garone et al. · PLoS Medicine Open access	4 Sep 2012	256
29	Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial Elizabeth Lucy Corbett, Tsitsi Bandason, Trinh Duong et al. · The Lancet Open access	Oct 2010	255
30	Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas Henri Diacon, Daniel E. Everitt et al. · The Lancet Open access	23 Mar 2015	251
31	A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control Gavin Churchyard, Katherine Fielding, James J. Lewis et al. · New England Journal of Medicine Open access	22 Jan 2014	244
32	Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae Nicolas A. Menzies, Matthew Quaife, Brian W Allwood et al. · The Lancet Global Health Open access	16 Nov 2021	238
33	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults Glenda Gray et al. · New England Journal of Medicine Open access	24 Mar 2021	238
34	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF Gavin Churchyard, Wendy Susan Stevens, Lerole David Mametja et al. · The Lancet Global Health Open access	14 Jul 2015	220
35	WHO global research priorities for antimicrobial resistance in human health Silvia Bertagnolio et al. · The Lancet Microbe Open access284 authors	13 Aug 2024	217
36	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa Paul Mee, Katherine Fielding, Salome Charalambous et al. · AIDS	10 Sep 2008	216
37	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models Rein M G J Houben et al. · The Lancet Global Health Open access	10 Oct 2016	212
38	Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies Wilton B. Williams et al. · Science Open access	30 Jul 2015	206
39	Epidemiology of HIV-associated tuberculosis Stephen D Lawn, Gavin Churchyard · Current Opinion in HIV and AIDS Open access	3 Jun 2009	195
40	Clinical standards for the assessment, management and rehabilitation of post-TB lung disease Giovanni Battista Migliori et al. · The International Journal of Tuberculosis and Lung Disease Open access	Oct 2021	192
41	Tuberculosis control in South Africa: Successes, challenges and recommendations Gavin Churchyard, Lerole David Mametja, Lindiwe Mvusi et al. · South African Medical Journal Open access	20 Jan 2014	176
42	Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B Christopher J. Hoffmann, Salome Charalambous, Chloe L. Thio et al. · AIDS	Jun 2007	172
43	The economic burden of TB diagnosis and treatment in South Africa Nicola Foster, Anna Vassall, Susan May Cleary et al. · Social Science & Medicine Open access	27 Jan 2015	168
44	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial Thomas J. Scriba et al. · The Lancet Infectious Diseases Open access162 authors	25 Jan 2021	162
45	"That is why I stopped the ART": Patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme Mison Dahab, Salome Charalambous, ROBIN D. HAMILTON et al. · BMC Public Health Open access	18 Feb 2008	160
46	Tuberculosis Vaccines and Prevention of Infection Thomas R. Hawn, Tracey A. Day, Thomas J. Scriba et al. · Microbiology and Molecular Biology Reviews ReviewOpen access	26 Nov 2014	158
47	HIV and tuberculosis in prisons in sub-Saharan Africa Lilanganee Telisinghe, Salome Charalambous, Stephanie M. Topp et al. · The Lancet Open access	16 Jul 2016	152
48	Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Conor Tweed, Rodney Dawson, Divan Aristo Burger et al. · The Lancet Respiratory Medicine Open access	12 Nov 2019	150
49	Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection Andre S. Nell, Eva D’lom, Patrick J. Bouic et al. · PLoS ONE Open access	26 Feb 2014	145
50	Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Violet N Chihota, Alfred D. Grant, Katherine Fielding et al. · PubMed	Aug 2010	143

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.